Stuart Millstone
Pulmonary Disease · Orange Park, FLNPI 1568481224
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 98 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 23.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,141 and has fallen 99.1% since, to $20 in 2024. That places this record below the midpoint for pulmonary disease clinicians in FL, where the typical reported total is $2,936.
Across 98 payments — averaging $38.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$895
- Grifols USA, LLC$614
- AstraZeneca$484
- Boehringer Ingelheim$454
- Insmed, Inc.$261
- Regeneron Healthcare Solutions, Inc.$228
- plus $804 from 14 others
What the payments were for
- Food & beverage$3,66598%
- Education$752%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 16 | $895 |
| Grifols USA, LLC | 10 | $614 |
| AstraZeneca | 11 | $484 |
| Boehringer Ingelheim | 18 | $454 |
| Insmed, Inc. | 6 | $261 |
| Regeneron Healthcare Solutions, Inc. | 6 | $228 |
| Genentech USA, Inc. | 6 | $186 |
| Novo Nordisk | 1 | $125 |
| Vapotherm Inc | 1 | $123 |
| Sunovion Pharmaceuticals Inc. | 4 | $61 |
| Mylan Specialty L.p. | 3 | $56 |
| Sanofi | 3 | $53 |
| Jazz Pharmaceuticals Inc. | 2 | $38 |
| Shire North American Group Inc | 2 | $33 |
| Circassia Inc. | 2 | $31 |
| Novartis | 2 | $31 |
| Gilead | 2 | $29 |
| Philips North America LLC | 1 | $14 |
| CSL Behring | 1 | $12 |
| Bayer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$480
- Prolastin-C Liquid$384
- XOLAIR$125
- Prolastin-C$125
- Ozempic$125
- OFEV$124
- Precision Flow$123
- Arikayce$122
- BREZTRI$121
- NUCALA$117
- DUPIXENT$101
How this compares
$3,740 in reported general payments places this provider in the 50th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Orange Park
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
- Domenick ReinaTampa$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.